Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
A Phase II, Randomised, Double Blind, Placebo Controlled, Six Way Crossover Study to Assess the Bronchodilator Effect of RPL554 Administered on Top of Salbutamol and Ipratropium in Patients With COPD.
This study evaluates the addition of RPL554 to standard reliever medications for chronic
obstructive pulmonary disorder (COPD). All patients will receive the same six treatments in
a randomised sequence:
1. salbutamol,
2. ipratropium,
3. salbutamol + RPL554,
4. ipratropium + RPL554,
5. RPL554
6. Placebo
Status | Completed |
Enrollment | 36 |
Est. completion date | December 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Provide informed consent - Males not donating sperm and using adequate contraception or females who are surgically sterile or postmenopausal - 12-lead ECG showing:Heart rate 45 to 90 bpm, QTcF=450 msec, QRS =120 msec, PR interval =220 msec, no clinically significant abnormality - Capable of complying with all study restrictions and procedures including ability to use the study nebuliser correctly. - BMI 18 to 33 kg/m2 with a minimum weight of 45 kg. - COPD diagnosis for at least 1 year and clinically stable COPD in previous 4 weeks - Demonstrates reversibility to bronchodilator (two puffs of salbutamol followed by two puffs of ipratropium) via spirometry: - Post-bronchodilator FEV1/forced vital capacity (FVC) ratio of =0.70 - Post-bronchodilator FEV1 =40 % and =80% of predicted normal - =150 mL increase from pre-bronchodilator FEV1 - Chest X-ray showing no abnormalities - Meet the concomitant medication restrictions and be expected to do so for the rest of the study. - Smoking history of =10 pack years. - Capable of withdrawing from long acting bronchodilators throughout the study and short acting bronchodilators for 8 hours prior to study treatment. Exclusion Criteria: - History of life-threatening COPD including Intensive Care Unit admission and/or requiring intubation. - COPD exacerbation requiring oral steroids in the previous 3 months - History of one or more hospitalisations for COPD in the previous 12 months - Respiratory tract infection (both upper and lower) treated with antibiotics in previous 12 weeks - Evidence of cor pulmonale or clinically significant pulmonary hypertension. - Other respiratory disorders - Previous lung resection or lung reduction surgery. - Oral therapies for COPD in the previous 3 months and throughout the study. - Drug or alcohol abuse in the past 3 years - Received an experimental drug within 3 months or five half lives, whichever is longer. - Prior exposure to RPL554 - Patients with a history of chronic uncontrolled disease that the Investigator believes are clinically significant. - Documented cardiovascular disease in last 3 months - Major surgery, (requiring general anaesthesia) in the previous 6 weeks, or will not have fully recovered from surgery, or planned surgery through the end of the study. - History of malignancy of any organ system within 5 years with the exception of localised skin cancers (basal or squamous cell) - Clinically significant abnormal values for safety laboratory tests - A disclosed history, or one known to the Investigator, of significant non compliance in previous investigational studies or with prescribed medications. - Requires oxygen therapy, even on an occasional basis. - Inability to adequately perform whole body plethysmography. - Any other reason that the Investigator considers makes the subject unsuitable to participate. - Patients with known hypersensitivity to atropine or its derivatives, or to ipratropium bromide, salbutamol or RPL554 or their excipients/components. |
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Medicines Evaluation Unit | Manchester |
Lead Sponsor | Collaborator |
---|---|
Verona Pharma plc |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 8 hour spirometry | Forced expired volume in one second (FEV1) over 8 hours post-dose | 8 hours | No |
Secondary | 12 hour spirometry | FEV1 over 4, 6 and 12 hours post-dose | 12 hours | No |
Secondary | Whole body plethysmography | Functional residual capacity, residual volume, total lung capacity, specific airway conductance, specific airway resistance at 1 and 4 hours post-dose | 4 hours | No |
Secondary | Area under the curve (AUC) | AUC for RPL554 plasma concentration | 12 hours | No |
Secondary | Maximum plasma concentration (Cmax) | Cmax for RPL554 plasma concentration | 12 hours | No |
Secondary | Time to maximum plasma concentration (Tmax) | Tmax for RPL554 plasma concentration | 12 hours | No |
Secondary | Adverse events | Continuous measurement of adverse events throughout the study | Up to 94 days | Yes |
Secondary | Safety laboratory tests | Laboratory safety tests at screening, before each treatment and end of study | Up to 94 days | Yes |
Secondary | ECG | 12 lead ECG at screening, before and up to 12 hours after each treatment and end of study | Up to 94 days | Yes |
Secondary | Vital signs | Blood pressure and pulse rate at screening, before and up to 12 hours after each treatment and end of study | Up to 94 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|